Last reviewed · How we verify
Double Blind Varenicline
At a glance
| Generic name | Double Blind Varenicline |
|---|---|
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Trial of Electronic Cigarettes With or Without Nicotine in Smoking Cessation. (PHASE3)
- Efficacy of Varenicline Tartrate in Treating Frequent Premature Ventricular Contractions (PHASE2)
- Varenicline for Nicotine Vaping Cessation in Adolescents (PHASE4)
- Varenicline and Bupropion for Alcohol Use Disorder (PHASE2)
- Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia (PHASE4)
- Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation (PHASE4)
- A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence (PHASE2)
- Smoking Cessation Study In Healthy Adolescent Smokers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Double Blind Varenicline CI brief — competitive landscape report
- Double Blind Varenicline updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI